• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Flora Growth Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    12/16/24 1:10:19 PM ET
    $FLGC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $FLGC alert in real time by email
    Flora Growth Corp.: Form 8-K - Filed by newsfilecorp.com

    false 2024-12-13 0001790169 00-0000000 Flora Growth Corp. 0001790169 2024-12-13 2024-12-13

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    ___________________________

    FORM 8-K

    CURRENT REPORT
    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): December 16, 2024 (December 13, 2024)

    FLORA GROWTH CORP.
    (Exact name of registrant as specified in its charter)

    Ontario 001-40397 Not Applicable
    (State or other jurisdiction (Commission (IRS Employer
    of incorporation) File Number) Identification No.)

    3230 W. Commercial Boulevard, Suite 180
    Fort Lauderdale, Florida, United States 33309
    (Address of principal executive offices) (ZIP Code)

    Registrant’s telephone number, including area code: (954) 842-4989

    Not Applicable
    (Former name or former address, if changed since last report)

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

    Title of each class   Trading Symbols   Name of each exchange on which registered
    Common Shares, no par value   FLGC   NASDAQ Capital Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b -2 of this chapter).

    Emerging growth company ☑

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐


    Item 1.01 Entry into a Material Definitive Agreement

    Registered Direct Offering

    On December 13, 2024, Flora Growth Corp., a corporation organized under the laws of the Province of Ontario ("Flora" or the "Company"), entered into a securities purchase agreement (the "Securities Purchase Agreement") with certain institutional investors (the "Investors") in connection with the issuance and sale by the Company in a registered direct offering (the "Registered Direct Offering") of 2,850,000 of the Company's common shares, no par value per share (the "Common Shares" and, such number of Common Shares issued and sold in the Registered Direct Offering, the "Offered Shares"), pursuant to the Company's effective shelf registration statement on Form S-3, as amended (File No. 333-274204), and a related base prospectus, together with the related prospectus supplement dated as of December 13, 2024 (such registration statement, prospectus and prospectus supplement, collectively, the "Registration Statement"), filed with the Securities and Exchange Commission.

    Pursuant to a placement agent agreement dated December 13, 2024 (the "Placement Agent Agreement"), Aegis Capital Corp. ("Aegis") acted as placement agent in connection with the Registered Direct Offering. The Company agreed to pay Aegis a placement commission equal to 7.0% of the gross proceeds raised in the Registered Direct Offering or a 3.0% placement commission for any investors introduced by the Company to Aegis who are not existing Aegis investors. The Company will also reimburse Aegis for legal fees of up to $75,000 and other reasonable and documented out-of-pocket expenses incurred in connection with the Registered Direct Offering.

    The net proceeds from the Registered Direct Offering were approximately $3.1 million after deducting Aegis' fees and other estimated expenses relating to the Registered Direct Offering. The Company intends to use the net proceeds from the Registered Direct Offering, together with its existing cash, for general corporate purposes and working capital.

    The Securities Purchase Agreement includes customary representations, warranties and covenants by the Company and the Investors. Additionally, the Company has agreed to provide the Investors with customary indemnification under the Securities Purchase Agreement against certain liabilities, including liabilities under the Securities Act of 1933, as amended.

    The closing of the issuance of the Offered Shares is expected to occur on December 16, 2024.

    The foregoing description of the Securities Purchase Agreement and the Placement Agent Agreement is only a summary and is qualified in its entirety by reference to the complete text of the Securities Purchase Agreement and the Placement Agent Agreement, copies of which are attached as Exhibit 10.1 and Exhibit 10.2, respectively, to this Report on Form 8-K and are incorporated by reference herein and into the Registration Statement.

    Copies of the opinion of Miller Thomson LLP regarding the validity of the Offered Shares is filed as Exhibit 5.1 to this Report on Form 8-K and are incorporated by reference into the Company's registration statement on Form S-3 (File No. 333-274204), filed with the Securities and Exchange Commission.

    Item 9.01 Financial Statements and Exhibits.

    (d) Exhibits

    5.1 Opinion of Miller Thomson LLP
    10.1 Securities Purchase Agreement, dated December 13, 2024, by and between the Company and the purchasers identified therein
    10.2  Placement Agent Agreement, dated as of December 13, 2024, by and between the Company and Aegis
    23.1 Consent of Miller Thomson LLP (included in Exhibit 5.1)
    104 Cover Page Interactive Data File (formatted as inline XBRL)


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

      FLORA GROWTH CORP.
         
    Date: December 16, 2024 By: /s/ Clifford Starke
      Name: Clifford Starke
      Title: Chief Executive Officer

     

    Get the next $FLGC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $FLGC

    DatePrice TargetRatingAnalyst
    11/25/2024$4.00Buy
    Aegis Capital
    10/13/2021$10.00Buy
    Roth Capital
    6/23/2021$6.00Buy
    MKM Partners
    More analyst ratings

    $FLGC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Flora Growth Corp. Announces Name Change to ZeroStack Corp., Furthering Its Strategy as an AI-Focused Asset Management Company

    Toronto, Ontario--(Newsfile Corp. - January 27, 2026) - Flora Growth Corp. (NASDAQ:FLGC) (the "Company") today announced that it will change its corporate name to "ZeroStack Corp." The name change is expected to become effective on or around January 29, 2026, on the Nasdaq Capital Market (the "Nasdaq"). Concurrent with the corporate name change, the Company's common shares (the "Common Shares") will trade on the Nasdaq under the symbol "ZSTK".The name and ticker change reflect the Company's evolution toward an AI-focused, asset management strategy with its first investment in $0G, the native asset of the 0G decentralized AI operating system ("0G Token").ZeroStack is focused on providing expo

    1/27/26 8:00:00 AM ET
    $FLGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SRx Health Solutions Appoints Sammy Dorf to Board of Directors

    TAMPA, Fla., Nov. 10, 2025 (GLOBE NEWSWIRE) -- SRx Health Solutions, Inc. (NYSE:SRXH) (the "Company") today announced the appointment of Sammy Dorf, Esq. to its Board of Directors. Sammy is a pioneering force in the modern cannabis economy and one of the industry's most accomplished dealmakers, strategists, and growth architects. Most recently serving as Executive Chairman of Flora Growth Corp. (NASDAQ:FLGC), Sammy guided the company through a transformative phase marked by innovation, disciplined expansion, and a strategic transition into a crypto treasury company. With nearly a decade of leadership at the intersection of cannabis, capital markets, and strategic development, Sammy b

    11/10/25 8:00:00 AM ET
    $FLGC
    $SRXH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Beverages (Production/Distribution)
    Consumer Staples

    Flora Growth Corp. Announces Second Purchase of 0G, the Fuel of the 0G Decentralized AI Network

    Fort Lauderdale, Florida--(Newsfile Corp. - October 21, 2025) - Flora Growth Corp. (NASDAQ:FLGC) (the "Company"), which is set to rebrand as ZeroStack, and is the first public company to offer exposure to Decentralized AI through the accumulation of $0G, the native cryptocurrency of the distributed AI infrastructure project 0G ("0G"), today announced the purchase of 880,025 $0G at an average price of $2.27. The purchase represents the Company's second acquisition of $0G since its most recent $401 million fundraising and strategic shift to build the world's first publicly listed 0G treasury.Below is a summary of the Company's current $0G position and key per-share metrics as of October 21, 20

    10/21/25 8:00:00 AM ET
    $FLGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FLGC
    SEC Filings

    View All

    Flora Growth Corp. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits

    8-K - ZeroStack Corp. (0001790169) (Filer)

    1/29/26 5:20:48 PM ET
    $FLGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by Flora Growth Corp.

    424B5 - Flora Growth Corp. (0001790169) (Filer)

    1/27/26 5:25:46 PM ET
    $FLGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form FWP filed by Flora Growth Corp.

    FWP - Flora Growth Corp. (0001790169) (Subject)

    1/27/26 4:05:35 PM ET
    $FLGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FLGC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Zeifman Laurence

    3 - Flora Growth Corp. (0001790169) (Issuer)

    1/15/26 11:54:20 AM ET
    $FLGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by CFO Vaiman Dany

    4 - Flora Growth Corp. (0001790169) (Issuer)

    12/22/25 5:15:05 PM ET
    $FLGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by CEO Reis-Faria Daniel

    4 - Flora Growth Corp. (0001790169) (Issuer)

    12/22/25 5:13:21 PM ET
    $FLGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FLGC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO Starke Clifford bought $6,455 worth of shares (6,795 units at $0.95), increasing direct ownership by 13,324% to 6,846 units (SEC Form 4)

    4 - Flora Growth Corp. (0001790169) (Issuer)

    9/17/24 10:17:39 AM ET
    $FLGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Wolkin Harold bought $24,255 worth of shares (25,000 units at $0.97) (SEC Form 4)

    4 - Flora Growth Corp. (0001790169) (Issuer)

    9/11/24 5:43:51 PM ET
    $FLGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO Starke Clifford bought $48 worth of shares (51 units at $0.95), increasing direct ownership by 0.01% to 474,046 units (SEC Form 4)

    4 - Flora Growth Corp. (0001790169) (Issuer)

    9/6/24 5:25:10 PM ET
    $FLGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FLGC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Aegis Capital initiated coverage on Flora Growth with a new price target

    Aegis Capital initiated coverage of Flora Growth with a rating of Buy and set a new price target of $4.00

    11/25/24 8:07:10 AM ET
    $FLGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Roth Capital initiated coverage on Flora Growth with a new price target

    Roth Capital initiated coverage of Flora Growth with a rating of Buy and set a new price target of $10.00

    10/13/21 9:00:51 AM ET
    $FLGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MKM Partners initiated coverage on Flora Growth with a new price target

    MKM Partners initiated coverage of Flora Growth with a rating of Buy and set a new price target of $6.00

    6/23/21 5:36:01 AM ET
    $FLGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FLGC
    Leadership Updates

    Live Leadership Updates

    View All

    SRx Health Solutions Appoints Sammy Dorf to Board of Directors

    TAMPA, Fla., Nov. 10, 2025 (GLOBE NEWSWIRE) -- SRx Health Solutions, Inc. (NYSE:SRXH) (the "Company") today announced the appointment of Sammy Dorf, Esq. to its Board of Directors. Sammy is a pioneering force in the modern cannabis economy and one of the industry's most accomplished dealmakers, strategists, and growth architects. Most recently serving as Executive Chairman of Flora Growth Corp. (NASDAQ:FLGC), Sammy guided the company through a transformative phase marked by innovation, disciplined expansion, and a strategic transition into a crypto treasury company. With nearly a decade of leadership at the intersection of cannabis, capital markets, and strategic development, Sammy b

    11/10/25 8:00:00 AM ET
    $FLGC
    $SRXH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Beverages (Production/Distribution)
    Consumer Staples

    Flora Growth Corp. Appoints BitGo as Custodian for $0G Treasury

    Fort Lauderdale, Florida--(Newsfile Corp. - October 16, 2025) - Flora Growth Corp. (NASDAQ:FLGC), which is set to rebrand as ZeroStack (the "Company"), the first and largest decentralized AI treasury company, has appointed BitGo Trust Company, Inc. ("BitGo") to provide institutional-grade custody for the Company's $0G treasury.BitGo, the digital asset infrastructure company, has enabled its clients to securely navigate the digital asset space since 2013 by delivering custody, wallets, staking, trading, financing, and settlement services from regulated cold storage. The appointment of BitGo is proof of the Company's focused approach to transparency, security, regulatory compliance and operati

    10/16/25 8:00:00 AM ET
    $FLGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Flora Growth Corp. Appoints Clifford Starke as Chief Executive Officer and Dany Vaiman as Chief Financial Officer; Regains Compliance with NASDAQ Minimum Bid Requirement

    Fort Lauderdale, Florida--(Newsfile Corp. - June 27, 2023) - Flora Growth Corp. (NASDAQ:FLGC) ("Flora" or the "Company"), a consumer-packaged goods leader serving all 50 states with 15,000+ points of distribution around the world and a pharmaceutical distributor in 28 countries, announced today that Clifford Starke has been appointed as Chief Executive Officer to lead its global operations and Dany Vaiman has been appointed as Chief Financial Officer. Mr. Starke, who previously served as President of the Company, takes over for Hussein Rakine, who resigned as CEO but will remain on the Company's Board of Directors. Mr. Rakine expressed his confidence in the appointment, stating, "Clifford's

    6/27/23 4:05:00 PM ET
    $FLGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FLGC
    Financials

    Live finance-specific insights

    View All

    Flora Growth Sets Third Quarter 2022 Conference Call for November 28, 2022, at 4:30 P.M. ET

    Flora Growth Corp. (NASDAQ:FLGC) ("Flora'' or the "Company"), a leading all-outdoor cultivator, manufacturer and distributor of global cannabis products and brands, will host its third quarter 2022 earnings call via webcast on Monday, November 28 at 4:30 p.m. ET. During the webcast, Flora management will deliver financial and operational results for the third quarter ended September 30, 2022, and provide updates on Flora's commercial wholesale operations, house of brands and life sciences division strategies. Following the webcast, Flora management will open the call to analysts, media and investors in a Q&A format. Live Webcast Details Date: Monday, November 28, 2022 Time: 4:30 p.m. ET

    11/21/22 7:05:00 AM ET
    $FLGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Flora Growth to Host Webcast Discussing M&A Activity and International Market Opportunities - Wednesday, October 26, 2022

    Flora Growth Corp. (NASDAQ:FLGC) ("Flora'' or the "Company"), a leading all-outdoor cultivator, manufacturer and distributor of global cannabis products and brands, announced today that the Company will be hosting an analyst call on Wednesday, October 26, 2022, at 02:00 p.m. EST via webcast to discuss Flora Growth's recent M&A activity and strategic growth opportunities. The conference call and live webcast will invite analysts to pose questions to Flora and Franchise Global Health's leadership teams regarding the recent announcement of the definitive agreement of acquisition between the two companies and the opportunities within the cannabis industry on the global stage. To access this ca

    10/25/22 7:05:00 AM ET
    $FLGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Flora Growth Awarded Best M&A Deal at Benzinga Cannabis Capital Conference

    Flora Growth Corp. (NASDAQ:FLGC) ("Flora" or the "Company"), a leading all-outdoor cultivator, manufacturer and distributor of global cannabis products and brands, today announced that the Company received the Best M&A Deal award at Benzinga's 2022 Cannabis Capital Conference in Chicago. "We are honored to receive the award for Best M&A Deal at the Benzinga Cannabis Capital Conference, which recognizes our strategic M&A objectives including acquiring products, expertise, expanding distribution, and customers," said Luis Merchan, Chairman and CEO of Flora. Flora completed the acquisition of JustCBD in February 2022, and it immediately offered the Company an established CPG brand with a por

    9/13/22 7:05:00 AM ET
    $FLGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FLGC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Flora Growth Corp.

    SC 13D/A - Flora Growth Corp. (0001790169) (Subject)

    12/17/24 8:02:53 PM ET
    $FLGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Flora Growth Corp.

    SC 13D/A - Flora Growth Corp. (0001790169) (Subject)

    12/17/24 8:01:40 PM ET
    $FLGC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Flora Growth Corp.

    SC 13G/A - Flora Growth Corp. (0001790169) (Subject)

    11/14/24 2:24:54 PM ET
    $FLGC
    Biotechnology: Pharmaceutical Preparations
    Health Care